Real-world effectiveness and safety of direct-acting antivirals for the treatment of hepatitis C virus in kidney and liver transplant recipients: experience of a large transplant center in Brazil
In conclusion, DAA treatment resulted in high rates of SVR and was well tolerated in both kidney and liver transplant patients. Adverse events were frequent but not severe in most patients, with low treatment drop-out rates. Interactions with immunosuppressants need monitoring since dose adjustments may be required. Reporting real-life experiences is important to help build evidence for patient management in non-controlled environments.PMID:38055377 | PMC:PMC10703500 | DOI:10.1590/S1678-9946202365059
Source: Revista do Instituto de Medicina Tropical de Sao Paulo - Category: Tropical Medicine Authors: Larissa Sgaria Pacheco Pedro Enrico Ventura Roger Kist Valter Duro Garcia Gisele Meinerz Cristiane Valle Tovo Guido Pio Cracco Cantisani Maria Lucia Zanotelli Marcos Mucenic Elizete Keitel Source Type: research
More News: Brazil Health | Environmental Health | Hepatitis | Hepatitis C | Kidney Transplant | Kidney Transplantation | Liver | Liver Transplant | Study | Transplant Surgery | Transplants | Tropical Medicine | Urology & Nephrology | Virology